Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for REC-1245 in Cancer. The expected timing is based on the latest available company guidance and may change.
DAHLIA trial. 10/02/24- Received IND clearance. 12/3/24- First patient dosed. 2/27/25- DAHLIA Ph1/2 trial initiated. 8/5/25- Early Ph1 PK & safety data in H1 2026. 11/05/25:- Early Ph1 monotherapy safety and PK data expected in H1 2026. 02/25/26:- Early Ph1 monotherapy safety and PK data still expected in H1 2026. 05/06/26:- DAHLIA Ph1/2 showed well-tolerated safety, no DLTs, dose-dependent PK. Additional dose-escalation data expected H2 2026. 08/05/26:- Additional Ph1 dose escalation data reiterated for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.